Share This Page
Investigational Drug Information for Tariquidar
✉ Email this page to a colleague
What is the development status for investigational drug Tariquidar?
Tariquidar is an investigational drug.
There have been 10 clinical trials for Tariquidar.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2002.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Neuralgia. The leading clinical trial sponsors are National Cancer Institute (NCI), QLT Inc., and Washington University School of Medicine.
Summary for Tariquidar
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,870 |
| WIPO Patent Applications | 716 |
| Japanese Patent Applications | 31 |
| Clinical Trial Progress | Phase 2 (2002-06-01) |
| Vendors | 67 |
Recent Clinical Trials for Tariquidar
| Title | Sponsor | Phase |
|---|---|---|
| Tariquidar-ondansetron Combination in Neuropathic Pain | Washington University School of Medicine | Phase 1/Phase 2 |
| Pgp Transporter and CNS Biodistribution of Ondansetron in Healthy Volunteers | Washington University School of Medicine | Phase 1 |
| Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors | National Cancer Institute (NCI) | N/A |
Clinical Trial Summary for Tariquidar
Top disease conditions for Tariquidar
Top clinical trial sponsors for Tariquidar
US Patents for Tariquidar
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Tariquidar Development Update and Market Projection
What is tariquidar’s clinical and regulatory status?
Tariquidar is a small-molecule ATP-binding cassette (ABC) transporter inhibitor, historically positioned as a P-glycoprotein (P-gp, ABCB1) and breast cancer resistance protein (BCRP, ABCG2) reversal agent intended to increase intracellular exposure of co-administered anticancer agents. Most development activity has occurred in oncology combination settings, with the investigational use depending on achieving transporter inhibition sufficient to alter pharmacokinetics and/or tumor drug exposure.
Development status snapshot (high-level):
- Tariquidar development has largely shifted from early clinical evaluation into a long period of limited late-stage, registrational-grade activity compared with other chemosensitizers.
- Public domain records show repeated oncology combination studies across past years, but no widely recognized, current, late-stage pivotal program that has culminated in a marketing authorization for tariquidar as a stand-alone product (regulatory endpoints typically require demonstrated clinical benefit in controlled trials).
- As of current public sources, tariquidar remains an investigational agent in oncology transporter modulation rather than an approved therapy.
Implication for “development update”:
- The investment case for tariquidar is constrained by the absence of a clearly established, modern, large randomized phase 3 readout in the public record that translates transporter inhibition into a statistically and clinically meaningful survival or response endpoint across a defined regimen and line of therapy.
- The competitive landscape for chemosensitization has also evolved, with newer targeted approaches and better-optimized delivery or next-generation transporter modulators in clinical use.
What does the patent landscape suggest for timeline risk and exclusivity?
Tariquidar’s core patents were filed years ago and have largely been worked through via expiring compositions, salts, and/or use claims typical for older oncology small molecules. Unless there are later-filed patents covering new combinations, dosing regimens, patient selection biomarkers, or new chemical entities (new generation derivatives), exclusivity duration in major markets is likely limited.
Commercial exclusivity levers commonly needed for tariquidar-like agents
- New combination claim coverage (specific anticancer drug(s), schedules, dosing ratios)
- Biomarker-based patient selection (ABCB1/ABCG2 expression, functional transporter activity assays)
- Formulation and delivery (e.g., solid dispersion, nanoparticle, or pharmacokinetic-optimized regimen)
- Mechanism-expanded claims (e.g., additional transporter targets or pathway interactions)
In the absence of a clearly established late-stage registrational program and a continuously refreshed patent estate, tariquidar’s exclusivity profile in practice tends to be a second-order constraint compared with clinical proof.
What is the market today for transporter modulators and chemosensitizers in oncology?
Market sizing logic for tariquidar A transporter inhibitor like tariquidar does not sell as monotherapy in a typical model. It is monetized via:
- Combination use with specific chemotherapy backbones or targeted agents.
- Regimen-level reimbursement where the transporter inhibitor is reimbursed as an add-on.
- Line-of-therapy access (front-line vs later lines) where incremental benefit is most defensible.
Where transporter modulation sits in the oncology market
- Oncology combination drugs are measured by the addressable population that receives the partner agents in eligible settings.
- A transporter inhibitor’s “effective market” depends on adoption by guideline-driven practice, which in turn depends on a proven clinical benefit beyond pharmacokinetic modulation.
Practical market reality
- Many chemosensitizer approaches have failed to show broad, consistent clinical benefit in later trials versus the added toxicity and complexity of combination regimens.
- The market that remains is typically narrower: specific biomarkers, specific regimens, or niche clinical protocols.
How big can tariquidar be if it re-enters registrational-grade development?
Because no current, validated late-stage registrational endpoint is visible in the public record, the projection below is built on adoption mechanics rather than assuming broad label expansion. The projection frames tariquidar’s market as a scenario driven by whether it becomes a reimbursed combination partner in a defined oncology segment.
Scenario framework (3-lane)
| Parameter | Conservative case | Base case | Aggressive case |
|---|---|---|---|
| Indication scope | Single tumor type or biomarker-defined subset | 2-3 tumor types with specific backbone | Broad adoption across multiple tumors and lines |
| Partner regimens | 1-2 co-administered anticancer drugs | 2-4 partner regimens | 4-6 partner regimens |
| Adoption timing | Gradual guideline uptake | Moderate uptake in trial-to-practice | Rapid uptake in specialized oncology networks |
| Real-world penetration by Year 5 | Low | Moderate | High |
Implied commercial envelope (annual global peak sales)
Using typical add-on oncology combination dynamics, a transporter inhibitor’s peak sales usually land well below large global oncology biologics unless it becomes standard-of-care across major regimens.
| Time horizon | Conservative | Base | Aggressive |
|---|---|---|---|
| Year 3 sales | $0.05B | $0.15B | $0.30B |
| Year 5 sales | $0.10B | $0.30B | $0.60B |
| Year 7 peak (global) | $0.15B | $0.45B | $1.0B |
What drives the spread
- Magnitude of incremental clinical benefit (not just transporter inhibition)
- Safety/tolerability in multi-drug oncology regimens
- Pricing power and payer acceptance for “add-on” drugs
- Patents and exclusivity strength covering combinations and dosing
- Competition from other transporter-modulating strategies and improved drug formulations
What do current public clinical findings imply about efficacy and differentiation?
Tariquidar’s differentiation historically depended on:
- Strong transporter inhibition potency intended to enhance intracellular anticancer exposure.
- Compatibility with conventional chemotherapy regimens in combination protocols.
However, the translation from mechanistic reversal to durable clinical benefit is the key bottleneck. Transporter inhibition can reduce efflux, but clinical endpoints require that:
- Resistance driven by efflux is a dominant mechanism in the patient subset.
- The partner drug’s efficacy is actually limited by transporter-mediated pharmacokinetics.
- The inhibitor does not introduce prohibitive toxicity, pharmacokinetic interactions, or altered exposure that undermines the partner drug.
Who is the competitive set and how does it shape adoption?
Competitors in the “transporter modulation for overcoming multidrug resistance” category include:
- Other P-gp/BCRP inhibitors and next-generation modulators evaluated in oncology combinations.
- Alternative strategies that mitigate resistance without direct transporter inhibition, including:
- New cytotoxic agents less dependent on efflux transporters
- Delivery systems (nanoparticles, targeted delivery)
- Precision patient selection using biomarkers tied to transporter activity
Adoption impact
- Payers and clinicians adopt transporter inhibitors only when there is repeatable clinical benefit in an actionable subgroup with a manageable safety profile.
What are the practical development requirements to unlock a commercial market?
A credible path to a meaningful market (based on typical oncology adoption patterns) requires:
- A late-stage program with clear clinical endpoints (progression-free survival, overall survival, objective response) rather than pharmacokinetic-only outcomes.
- A regimen definition that ties tariquidar to a specific co-therapy backbone.
- A biomarker or functional selection strategy to enrich for efflux-driven resistance.
- A dosing strategy that ensures transporter inhibition without unacceptable interaction risk.
If development restarts with an undifferentiated population and nonspecific regimens, tariquidar’s uptake likely stays confined to academic protocols rather than reimbursement-led adoption.
What is the most likely market path if tariquidar re-enters the clinic?
The most likely market path for tariquidar is not “global standard of care,” but “reimbursed add-on in defined oncology segments”:
- First adoption: biomarker-selected or mechanism-informed use
- Second adoption: expansion to additional tumor types if benefit replicates
- Pricing: typically anchored to add-on value tied to improved outcomes rather than generic chemosensitizer economics
Key operational constraints that limit market capture
| Constraint | Effect on market |
|---|---|
| Add-on label complexity | Reduces broad payer adoption unless benefit is large and consistent |
| Safety and drug-drug interaction risk | Limits regimen scope and dosing flexibility |
| Patent estate refresh | Determines whether partners can block competition via exclusivity on combinations |
| Lack of registrational late-stage proof | Keeps use in trials and specialist settings |
Key Takeaways
- Tariquidar remains an investigational ATP-binding cassette transporter inhibitor conceptually focused on reversing efflux-mediated multidrug resistance in oncology combination therapy.
- The market upside hinges on clinical proof that mechanistic transporter inhibition translates into repeatable, clinically meaningful outcomes in defined regimens and potentially biomarker-selected populations.
- Without a clearly established, modern late-stage registrational program, tariquidar’s realistic market is likely confined to niche, protocol-driven adoption rather than broad standard-of-care penetration.
- If tariquidar re-enters registrational-grade development with a defined combination and selection strategy, plausible peak annual global sales ranges from roughly $0.15B to $1.0B depending on indication scope and adoption velocity.
FAQs
1) Is tariquidar an approved drug?
No. Tariquidar is used in the public record as an investigational oncology transporter inhibitor rather than an approved marketed therapy.
2) What is tariquidar’s mechanism of action?
Tariquidar inhibits ATP-binding cassette transporter efflux, historically targeting P-gp (ABCB1) and BCRP (ABCG2), with the intent to increase intracellular exposure of co-administered anticancer drugs.
3) Why is the commercial market for transporter inhibitors often limited?
Because pharmacokinetic reversal alone rarely guarantees clinical benefit across unselected populations, payers and guidelines require demonstrable outcome improvements with manageable safety and drug-drug interaction profiles.
4) What determines whether tariquidar can reach mainstream adoption?
A clear late-stage clinical benefit in a defined regimen and population, ideally supported by biomarker or functional selection that ties efflux to treatment response.
5) What is the biggest lever in a future valuation case for tariquidar?
The existence of registrational-quality clinical evidence paired with enforceable exclusivity that covers combinations, dosing, and patient selection.
References
[1] FDA. “Drug Development and Drug Interactions: Table of Transporters and Enzymes.” U.S. Food and Drug Administration. (General transporter interaction context). https://www.fda.gov
[2] U.S. National Library of Medicine. “Tariquidar” (substance overview and linked literature records). ClinicalTrials.gov / PubChem records. https://clinicaltrials.gov ; https://pubchem.ncbi.nlm.nih.gov
[3] PubChem. “Tariquidar” compound record (identification, mechanism-linked descriptors). https://pubchem.ncbi.nlm.nih.gov
[4] FDA Orange Book (where applicable to identify marketed status and related exclusivity; tariquidar search). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
More… ↓
